

Press release

Lomma 2026-02-04

THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, OR ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION WOULD REQUIRE ADDITIONAL PROSPECTUS, REGISTRATION OR OTHER MEASURES IN ADDITION TO THOSE REQUIRED BY SWEDISH LAW, IS PROHIBITED, OR OTHERWISE IS UNLAWFUL OR CANNOT BE MADE WITHOUT THE APPLICATION OF AN EXEMPTION FROM SUCH ACTION. REFER TO THE SECTION "IMPORTANT INFORMATION" AT THE END OF THIS PRESS RELEASE.

## Information regarding the final subscription day in Nexam Chemical's ongoing rights issue

**Monday, 9 February 2026, is the final day to subscribe for shares in Nexam Chemical Holding AB's (publ) ("Nexam Chemical" or the "Company") ongoing rights issue of shares of approximately SEK 51.8 million, which was announced by the Company on 22 December 2025 (the "Rights Issue"). Please note that certain banks and nominees may have an earlier deadline for subscription in the Rights Issue than 9 February 2026. Shareholders are therefore advised to check with their bank or nominee whether they have an earlier deadline for subscription. The last day of trading in subscription rights on Nasdaq First North Premier Growth Market is today, 4 February 2026.**

### Timetable for the Rights Issue

|                               |   |
|-------------------------------|---|
| 26 January – 4 February 2026  | Trading in subscription rights (TR) on Nasdaq First North Premier Growth Market.                    |
| 26 January – 9 February 2026  | Subscription period for the Rights Issue.   |
| 26 January – 27 February 2026 | Expected trading in paid subscribed shares (BTA) on Nasdaq First North Premier Growth Market.       |
| 11 February 2026              | Expected date for announcement of the outcome of the Rights Issue.                                  |
| Week 9, 2026                  | Registration of the Rights Issue with the Swedish Companies Registration Office (Sw. Bolagsverket). |

### Summary of the Rights Issue

The Board of Directors of Nexam Chemical resolved on 22 December 2025, with subsequent approval by the extraordinary general meeting of the Company on 19 January 2026, to carry out the Rights Issue in accordance with the following principal terms:

- The Rights Issue comprises a maximum of 21,577,544 new shares in the Company.
- The subscription price in the Rights Issue amounts to SEK 2.40 per share.
- Upon full subscription in the Rights Issue, the Company will receive approximately SEK 51.8 million, before deduction of issue-related costs, which are estimated to amount to approximately SEK 6.6 million, of which underwriting compensation amounts to approximately SEK 3.0 million, provided that all underwriters elect to receive cash compensation.

- Shareholders who were registered in the share register maintained by Euroclear Sweden AB on the record date of 22 January 2026 have preferential rights to subscribe for shares in the Rights Issue. Existing shareholders as of the record date will be allocated one (1) subscription right for each one (1) existing share held. Fifteen (15) subscription rights entitle the holder to subscribe for four (4) new shares.
- The subscription period in the Rights Issue runs from 26 January 2026 up to and including 9 February 2026.
- Approximately 22.1 per cent of the Rights Issue is covered by subscription undertakings and approximately 77.9 per cent by underwriting commitments, of which approximately SEK 20.0 million constitutes a so-called bottom underwriting and approximately SEK 20.4 million constitutes a so-called top underwriting. Neither the subscription undertakings nor the underwriting commitments are secured through bank guarantees, blocked funds, pledges or similar arrangements.
- Subscription undertakings have been entered into by the CEO, CFO and all members of the Board of Directors, as well as a number of the Company's larger existing shareholders. The underwriting commitments have been provided by both existing shareholders and external investors. The existing shareholders Claes Mellgren, Per Olof Andersson, Sven-Olov Hjälmstad and Mats Andersson have undertaken to subscribe for their entire pro rata share of the Rights Issue and have, in addition, entered into agreements regarding top underwriting, entailing an increased commitment in the Rights Issue.

The complete terms and conditions and instructions for the Rights Issue are set out in the information document published by the Company on 23 January 2026 (the "**Information Document**").

#### **Advisers**

Corpura Fondkommission AB, [www.corpura.se](http://www.corpura.se), is acting as Sole Coordinator and Bookrunner in connection with the Rights Issue. Setterwalls Advokatbyrå AB is acting as legal adviser to the Company in connection with the Rights Issue. Aqurat Fondkommission AB is acting as the issuing agent.

#### **IMPORTANT INFORMATION**

The release, announcement or distribution of this press release may, in certain jurisdictions, be subject to legal restrictions. The recipients of this press release in jurisdictions where this press release has been published or distributed shall inform themselves of and follow such legal restrictions. The recipient of this press release is responsible for using this press release, and the information contained herein, in accordance with applicable rules in each jurisdiction.

This press release does not constitute an offer, or a solicitation of any offer, to buy or subscribe for any securities in Nexam Chemical in any jurisdiction, neither from Nexam Chemical nor from someone else.

This press release is not a prospectus for the purposes of the Prospectus Regulation and has not been approved by any regulatory authority in any jurisdiction. No prospectus will be prepared in connection with the Rights Issue. The Company has prepared the Information Document in the form provided for in Annex IX to the Prospectus Regulation. The Information Document is available on the Company's website, [www.nexamchemical.com](http://www.nexamchemical.com). The Swedish Financial Supervisory Authority, which is the national

competent authority, has neither approved nor reviewed the Information Document. Each investor is advised to make their own assessment of whether it is appropriate to invest in the Company.

This press release does not identify or suggest, or purport to identify or suggest, the risks (direct or indirect) that may be associated with an investment in the Company. The information contained in this announcement relating to the Rights Issue is for background purposes only and does not purport to be full or complete. No reliance may be placed for any purpose on the information contained in this press release or its accuracy or completeness.

This press release does not constitute or form part of an offer or solicitation to purchase or subscribe for securities in the United States. The securities referred to herein may not be sold in the United States absent registration or an exemption from registration under the US Securities Act of 1933, as amended (the "**Securities Act**"), and may not be offered or sold within the United States absent registration or an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. There is no intention to register any securities referred to herein in the United States or to make a public Rights Issue of the securities in the United States. The information in this press release may not be announced, published, copied, reproduced or distributed, directly or indirectly, in whole or in part, within or into the USA, Australia, Belarus, Canada, Hong Kong, Japan, New Zealand, Russia, Singapore, South Africa, South Korea, Switzerland or in any other jurisdiction where such announcement, publication or distribution of the information would not comply with applicable laws and regulations or where such actions are subject to legal restrictions or would require additional registration or other measures than what is required under Swedish law. Actions taken in violation of this instruction may constitute a crime against applicable securities laws and regulations.

In the United Kingdom, this document and any other materials in relation to the securities described herein is only being distributed to, and is only directed at, and any investment or investment activity to which this document relates is available only to, and will be engaged in only with, "qualified investors" who are (i) persons having professional experience in matters relating to investments who fall within the definition of "investment professionals" in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order"); or (ii) high net worth entities falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as "relevant persons"). In the United Kingdom, any investment or investment activity to which this communication relates is available only to, and will be engaged in only with, relevant persons. Persons who are not relevant persons should not take any action on the basis of this press release and should not act or rely on it.

### **Forward-looking statements**

This press release contains forward-looking statements that reflect the Company's intentions, beliefs, or current expectations about and targets for the Company's and the group's future results of operations, financial condition, liquidity, performance, prospects, anticipated growth, strategies and opportunities and the markets in which the Company and the group operates. Forward-looking statements are statements that are not historical facts and may be identified by words such as "believe", "expect", "anticipate", "intend", "may", "plan", "estimate", "will", "should", "could", "aim" or "might", or, in each case, their negative, or similar expressions. The forward-looking statements in this press release are based upon various assumptions, many of which are based, in turn, upon further

assumptions. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, it can give no assurances that they will materialize or prove to be correct. Because these statements are based on assumptions or estimates and are subject to risks and uncertainties, the actual results or outcome could differ materially from those set out in the forward-looking statements as a result of many factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this release by such forward-looking statements. The Company does not guarantee that the assumptions underlying the forward-looking statements in this press release are free from errors and readers of this press release should not place undue reliance on the forward-looking statements in this press release. The information, opinions and forward-looking statements that are expressly or implicitly contained herein speak only as of its date and are subject to change without notice. Neither the Company nor anyone else undertake to review, update, confirm or to release publicly any revisions to any forward-looking statements to reflect events that occur or circumstances that arise in relation to the content of this press release, unless it is required by law or Nasdaq First North Premier Growth Market's rule book for issuers.

#### **Information to distributors**

Solely for the purposes of the product governance requirements contained within: (a) EU Directive 2014/65/EU on markets in financial instruments, as amended ("**MiFID II**"); (b) Articles 9 and 10 of Commission Delegated Directive (EU) 2017/593 supplementing MiFID II; and (c) local implementing measures (together, the "**MiFID II Product Governance Requirements**"), and disclaiming all and any liability, whether arising in tort, contract or otherwise, which any "manufacturer" (for the purposes of the MiFID II Product Governance Requirements) may otherwise have with respect thereto, the offered shares have been subject to a product approval process, which has determined that such shares are: (i) compatible with an end target market of retail investors and investors who meet the criteria of professional clients and eligible counterparties, each as defined in MiFID II; and (ii) eligible for distribution through all distribution channels as are permitted by MiFID II (the "**Target Market Assessment**").

Notwithstanding the Target Market Assessment, distributors should note that: the price of the shares in the Company may decline and investors could lose all or part of their investment; the shares in the Company offer no guaranteed income and no capital protection; and an investment in the shares in the Company is compatible only with investors who do not need a guaranteed income or capital protection, who (either alone or in conjunction with an appropriate financial or other adviser) are capable of evaluating the merits and risks of such an investment and who have sufficient resources to be able to bear any losses that may result therefrom. The Target Market Assessment is without prejudice to the requirements of any contractual, legal or regulatory selling restrictions in relation to the Rights Issue.

For the avoidance of doubt, the Target Market Assessment does not constitute: (a) an assessment of suitability or appropriateness for the purposes of MiFID II; or (b) a recommendation to any investor or group of investors to invest in, or purchase, or take any other action whatsoever with respect to the shares in the Company.

Each distributor is responsible for undertaking its own target market assessment in respect of the shares in the Company and determining appropriate distribution channels.

### **Foreign direct investments**

As Nexam Chemical is deemed to carry out activities worthy of protection in accordance with the Swedish Screening of Foreign Direct Investments Act (Sw. lag (2023:560) om granskning av utländska direktinvesteringar), certain investments in the Rights Issue may require examination by the Inspectorate of Strategic Products. More information about this is available on the Company's website, [www.nexamchemical.com](http://www.nexamchemical.com).

*Note: This press release has been translated from Swedish. The Swedish text shall govern for all purposes and prevail in case of any discrepancy with the English version.*

**For more information, please visit [www.nexamchemical.com](http://www.nexamchemical.com) or contact:**

Ronnie Törnqvist, VD, +46-706 25 41 85, [ronnie.tornqvist@nexamchemical.com](mailto:ronnie.tornqvist@nexamchemical.com)

---

### **About Nexam Chemical**

*Nexam Chemical develops technology and products that make it possible to significantly improve the production process and properties of most types of plastics in a cost-effective manner and with retained production technology. The improved properties include strength, toughness, temperature and chemical resistance as well as service life. The improvements in properties that can be achieved by using Nexam Chemical's technology make it possible to replace metals and other heavier or more expensive materials with plastics in a number of applications. In applications where plastic is already used, Nexam Chemicals products can improve the manufacturing process, reducing material use and enable more environmental friendly alternatives. Example of commercial applications: pipe manufacturing, foam production and high-performance plastics. More information about the business will be found on [www.nexamchemical.com](http://www.nexamchemical.com). The company's Certified Adviser is Bergs Securities AB. Bergs Securities AB can be reached at [info@bergssecurities.se](mailto:info@bergssecurities.se) or by phone +46-8 408 933 50.*